抗CD38单克隆抗体时代自体造血干细胞移植在系统性轻链淀粉样变性治疗中的作用
本文为观点文章,探讨在抗CD38单克隆抗体等高效浆细胞靶向治疗时代,大剂量美法仑联合自体造血干细胞移植(HDM-AHCT)在适合移植的系统性轻链淀粉样变性患者中作为一线和挽救治疗的作用及未解决的问题。文章指出初始治疗目标是尽快获得快速、深度的血液学缓解并辅以多学科支持治疗,由于缺乏随机对照试验数据支持HDM-AHCT优于标准剂量治疗,其地位正在被重新分析。
要点
- 初始治疗目标是尽快获得快速、深度的血液学缓解,同时由多学科团队提供支持治疗。
- 靶向浆细胞克隆的高效治疗可获得高血液学完全缓解率且治疗相关并发症和死亡率低。
- 缺乏随机对照试验数据支持HDM-AHCT优于标准剂量治疗,其一线和挽救治疗作用尚待明确。
核心结论
- 在抗CD38单克隆抗体时代,HDM-AHCT在适合移植的系统性轻链淀粉样变性患者中作为一线和挽救治疗的作用及未解决的问题有待探讨。
研究设计与样本
- 本文为观点文章,探讨HDM-AHCT在适合移植的系统性轻链淀粉样变性患者管理中的作用。
主要发现
- 靶向浆细胞克隆的高效治疗可获得高血液学完全缓解率且治疗相关并发症和死亡率低。
- 缺乏随机对照试验数据支持HDM-AHCT优于标准剂量治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The primary goal of the initial treatment in systemic light chain amyloidosis is to obtain a rapid and profound haematological response as safely as possible, coupled with supportive care by a multidisciplinary team. The treatment landscape has evolved with the introduction of highly effective therapies targeting the plasma cell clones, which can attain high rates of haematological complete response with minimal treatment-related morbidity and mortality. Consequently, the role of high-dose melphalan followed by autologous haematopoietic cell transplantation (HDM-AHCT) is being analysed, particularly considering the absence of randomised controlled trial data supporting its superiority over standard-dose therapies in systemic light chain amyloidosis treatment. In this Viewpoint, we will explore the role of HDM-AHCT in the management of patients with systemic light chain amyloidosis who are eligible for transplantation, and the unresolved questions surrounding HDM-AHCT use as both front-line and salvage therapy.
引用
- Chakraborty R, Milani P, Palladini G, et al. Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies. Lancet Haematol. 2023. PMID: 37802087. doi:10.1016/S2352-3026(23)00175-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。